Pharming wanted to buy back the rights to its own drug, but didn’t have the backing to pull it off. Kreos Capital had a remedy, writes Nathan Williams from Private Debt Investor Magazine.
Read the full report here.
Non-Sponsor Growth Debt – Kreos Capital & Pharming Report
